Biotech is getting more independent

The relationship between smaller biotechs and bigger pharmaceutical companies is morphing, according to a new analysis from BioCentury. Biotechs aren’t as dependent on their larger counterparts, and are now launching their own commercial products. Biotech companies like Alnylam and Agios accounted for 27 percent of drug launches in 2018, up from 11 percent in 2014. 

This means that the broader drug commercialization strategy might change up: Larger drug makers tend to pursue global rights for their products, whereas the lither biotechs tend to split up commercialization and development responsibilities among their peers.